16:44 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

Targeting TSLP

A team from the Benaroya Research Institute has demonstrated that the TSLP signaling pathway could be a new target to treat breast cancer. Thymic stromal lymphopoietin (TSLP) has shown conflicting roles in the context of...
18:16 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse experiments suggest inhibiting TSLP signaling could help treat breast cancer. In tissue samples from breast cancer patients, levels of TSLPR in tumors were higher than in adjacent normal...
20:02 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies identified two TSLPR - CD127 fusion proteins that could help treat allergy. One fusion protein consisted of the full extracellular domain of TSLPR linked to the N-terminus of the extracellular...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Thymic stromal lymphopoietin (TSLP); interleukin-33 (IL-33; NF-HEV); IL-25 (IL-17E)

Inflammation INDICATION: Inflammation; liver fibrosis; pulmonary fibrosis Mouse studies suggest combined inhibition of IL-33, TSLP and IL-25 could help treat cytokine-driven inflammation and fibrosis. In a mouse model of Schistosomiasis mansoni infection, systemic knockout of...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

RG7258: Development discontinued

Roche disclosed in its 1H12 earnings that it discontinued development of RG7258, which was in Phase I testing for asthma. In June, the pharma announced the closing of its R&D site in Nutley, N.J., which...
01:56 , Jul 27, 2012 |  BC Extra  |  Financial News

Roche reports sales for new cancer drugs

Roche (SIX:ROG; OTCQX:RHHBY) reported 1H12 sales for its three newest cancer products, including CHF4 million ($4 million) in sales of Perjeta pertuzumab since its launch in June to treat previously untreated HER2-positive metastatic breast cancer...
07:00 , Jul 16, 2012 |  BioCentury  |  Strategy

Burying Nutley

When Roche acquired Genentech Inc. in 2009, it was clear the pharma's Nutley, N.J., facility had been underperforming for years. Three years later, the continued poor performance of the Nutley site made it an obvious...
07:00 , Sep 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Dermatology Atopic dermatitis Thymic stromal lymphopoietin (TSLP); TSLP receptor (TSLPR; CLRF2); IL-4; IL-13 Studies in mice and in cell culture suggest...
07:00 , Sep 11, 2008 |  BC Innovations  |  Targets & Mechanisms

Skin-deep Target

There are at least a dozen approved drugs for eczema, but none for long-term or continuous treatment of the condition. First-line drugs such as corticosteroids cannot be used for more than a few consecutive weeks...